Étiquette : schizophrénie

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment, Tibor Stark, 2020,

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004     Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]

Lire la suite

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia, Fernanda F. Peres et al., 2018

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia Fernanda F. Peres, Mariana C. Diana, Raquel Levin, Mayra A. Suiama, Valéria Almeida, Ana M. Vendramini, Camila M. Santos, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abílio Frontiers in Pharmacology, 2018, 9, article 901. Doi : 10.3389/fphar.2018.00901   Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we investigated whether treatment with cannabidiol (CBD – a compound of Cannabis sativa that [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, avril 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, avril 2020.     1 - Généralités : 1 - 11 2 - Cannabidiol anxiolytique : 12 - 14 3 - Cannabidiol antipsychotique : 15 - 20 4 - Cannabinoïdes et dépression : 21 - 24 5 - Cannabidiol antidépresseur : 25 6 - Cannabinoïdes et Sommeil : 26 - 27 7 - Cannabinoïdes et addiction au Cannabis : 28 - 337 8 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 38 - 52 9 - Cannabinoides et syndrome de Gilles de la Tourette : 53 - 54 10 - Cannabinoides et Hyperactivité - Déficit de l’Attention (HA-DA, TDAH) : 55 - 56 11 - Cannabinoides et PTSD : 57 - 60 12 [...]

Lire la suite

What to Know About Peyote Use, Buddy T., VeryWellMind.com, 2020

What to Know About Peyote Use By   Buddy T Medically reviewed by   Steven Gans, MD VeryWell Mind.com, Updated on February 14, 2020 https://www.verywellmind.com/how-long-does-peyote-stay-in-your-system-80310 kedsirin jaidee / Getty Images   Peyote (Lophophora williamsii or Lophophora diffusa) is a small, spineless cactus that is found in the southwest United States, northern Mexico and Peru. The plant has been used for about six thousand years by native tribes for religious and healing purposes. Peyote's principal active ingredient is mescaline, a psychedelic compound that can also be man-made through chemical synthesis.1 The peyote buttons, protrusions found on the tops of the cactus plants, are usually dried and then chewed or [...]

Lire la suite

Cannabis consumption and the risk of psychosis, Alice Mulè et al., 2017

Cannabis consumption and the risk of psychosis Alice Mulè, Lucia Sideli, Giuseppe Colli, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray Evidence-based Psychiatric Care, 2017, 3, 25-31   Enfin, un article récent (novembre 2018) explorant la co-occurence "consommation de cannabis / troubles "psychotique"", qui plus est international (anglo-italien), et comprenant, parmi les signataires, les célèbres Robin Murray du Kings Collège londonien, et Marta Di Forti de l'Université de Palerme, qui énonce clairement l'incapacité épidémiologique à établir un lien de causalité entre "consommation de cannabis et éclosion de troubles "psychotique"" !!! : "Conclusions : The [...]

Lire la suite

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, Andreza B. Sonego et al., 2016

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042   Highlights  Cannabidiol (CBD) attenuated haloperidol-induced catalepsy.  CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol.  CBD effects were blocked by 5-HT1A receptor antagonist.   Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]

Lire la suite

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats, Ewa Kozela et al., 2019

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats Ewa Kozela & Martyna Krawczyk & Tomasz Kos & Ana Juknat & Zvi Vogel & Piotr Popik Molecular Neurobiology, 2019, Doi : 10.1007/s12035-019-01831-2   Abstract Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. The mechanisms of these beneficial effects of CBD are unknown. Here, we examined behavioral effects of CBD in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine (KET) administration. In parallel, we assessed transcriptional changes behind CBD activities in the prefrontal cortex (PFC), the [...]

Lire la suite

The therapeutic role of Cannabidiol in mental health : a systematic review, Khan R. at al., 2020

The therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y   Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]

Lire la suite

6 variétés de cannabis pleines de THCV, Aurélien BERNARD, Newsweed.fr, 30 janvier 2020

6 variétés de cannabis pleines de THCV Aurélien BERNARD Newsweed.fr, 30 janvier 2020 https://www.newsweed.fr/5-varietes-cannabis-thcv/ À mesure que les connaissances scientifiques sur le cannabis se développent, la composition chimique du cannabis et la manière dont il interagit avec le corps se dévoilent. Et si le CBD ou le THC sont largement étudiés, certains cannabinoïdes plus rares comme le THCV (tetrahydocannabivarine) intéressent de plus en plus les scientifiques. Au cours de la dernière décennie, des études sur des humains et des animaux ont identifié le potentiel du THCV pour réduire l’appétit chez les personnes qui luttent pour perdre du poids, réguler la glycémie chez les personnes atteintes [...]

Lire la suite

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, Jerome Sarris et al., 2020

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8   Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]

Lire la suite